Crizotinib and renal insufficiency: a case report and review of the literature.
A 69 year old man with idiopathic chronic kidney disease was diagnosed with relapsing EGFR negative, ALK positive lung adenocarcinoma, and treated with chemotherapy and antiangiogenic treatment, under which his renal insufficiency worsened. During second line crizotinib treatment, further worsening of the renal function was seen, with very clear correlation with crizotinib withdrawal and rechallenge. No further drug causes for the worsening blood creatinine values were detected.
Department of Hematology and Medical Oncology, Hospital Clínico Universitario de Valencia, Avda. Blasco Ibáñez 17, 46010 Valencia, Spain. Electronic address: paloma_martin@comv.es.
Paloma
P
Martín Martorell
Department of Hematology and Medical Oncology, Hospital Clínico Universitario de Valencia, Avda. Blasco Ibáñez 17, 46010 Valencia, Spain.
Marisol
M
Huerta Alvaro
Department of Nephrology, Hospital Clínico Universitario de Valencia, Avda. Blasco Ibáñez 17, 46010 Valencia, Spain.
Miguel A
MA
Solís Salguero
Department of Hematology and Medical Oncology, Hospital Clínico Universitario de Valencia, Avda. Blasco Ibáñez 17, 46010 Valencia, Spain.
Amelia
A
Insa Molla
D000230:Adenocarcinoma / Q000188:drug therapy*; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000077547:Crizotinib; D006801:Humans; D007677:Kidney Function Tests; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D051437:Renal Insufficiency / Q000139:chemically induced*
D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib
ALK; Crizotinib; Lung adenocarcinoma; Renal insufficiency; Toxicity; Tyrosine kinase inhibitors